Pureos Bioventures is a venture capital firm that specializes in providing funding for companies developing innovative therapeutics. With a focus on the next generation of biological drugs and drug formats, their goal is to advance innovative treatments for severe diseases and impact patients' lives. Their portfolio consists of companies working on breakthrough treatments for various severe diseases and conditions.

One such company is Acrivon Therapeutics, a clinical stage oncology company developing novel cancer drugs paired with companion diagnostics. Another is Alentis Therapeutics, a clinical-stage biopharmaceutical company focused on developing treatments for cancer and fibrotic diseases. In addition to their portfolio, Pureos Bioventures boasts an impressive team of career venture capitalists, biotech founders, former pharma and biotech executives, research scientists, medical doctors, and experienced drug developers.

This diverse team is united by their passion for biotech start-ups, innovation, and the quest for new and better medicines. Overall, Pureos Bioventures offers not only capital but also expertise and support to drive the success of innovative therapeutics companies and ultimately improve patient outcomes